Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Psychiatry
Volume 2013 (2013), Article ID 136194, 3 pages
Case Report

Glossopharyngeal Dystonia Secondary to a Lurasidone-Fluoxetine CYP-3A4 Interaction

University of Florida, Gainesville, FL 32606, USA

Received 17 April 2013; Accepted 8 May 2013

Academic Editors: N. Bass, M. Kluge, and C. Lançon

Copyright © 2013 Sean Paul et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. M. Abou-Setta, S. S. Mousavi, C. Spooner et al., “First-generation versus second-generation antipsychotics in adults: comparative effectiveness. Comparative effectiveness review No. 63. (Prepared by the University of Alberta Evidence-based Practice Center under Contract No. 290-2007-10021.),” AHRQ Publication 12-EHC054-EF, Agency for Healthcare Research and Quality, Rockville, Md, USA, May 2012. View at Google Scholar
  2. J. M. Pierre, “Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management,” Drug Safety, vol. 28, no. 3, pp. 191–208, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. C. B. Joy, C. E. Adams, and S. M. Lawrie, “Haloperidol versus placebo for schizophrenia,” Cochrane Database of Systematic Reviews, vol. 18, no. 4, Article ID CD003082, 2006. View at Google Scholar · View at Scopus
  4. A. A. Shirzadi and S. N. Ghaemi, “Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome,” Harvard Review of Psychiatry, vol. 14, no. 3, pp. 152–164, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. R. W. Buchanan, J. Kreyenbuhl, D. L. Kelly et al., “The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements,” Schizophrenia Bulletin, vol. 36, no. 1, pp. 71–93, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. Sunovion Pharmaceuticals, “Latuda: highlights of prescribing information,”
  7. A. F. Schatzberg and C. B. Nemeroff, The American Psychiatric Publishing Textbook of Psychopharmacology, American Psychiatric Publishing, Washington, DC, USA, 2009.
  8. L. Samalin, M. Garnier, and L. Pierre-Michel, “Clinical potential of lurasidone in the management of schizophrenia,” Therapeutics and Clinical Risk Management, vol. 7, pp. 239–250, 2011. View at Google Scholar
  9. R. J. Koek and E. H. Pi, “Acute laryngeal dystonic reactions (I: reply),” Psychosomatics, vol. 31, no. 2, p. 237, 1990. View at Google Scholar · View at Scopus
  10. C. Christodoulou and C. Kalaitzi, “Antipsychotic drug-induced acute laryngeal dystonia: two case reports and a mini review,” Journal of Psychopharmacology, vol. 19, no. 3, pp. 307–311, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Mellacheruvu, J. W. Norton, and J. Schweinfurth, “Atypical antipsychotic drug-induced acute laryngeal dystonia: 2 case reports,” Journal of Clinical Psychopharmacology, vol. 27, no. 2, pp. 206–207, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. B. J. Sadock, V. A. Sadock, and H. I. Kaplan, Kaplan & Sadock's Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 2003.